Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 586,562 shares of the biopharmaceutical company’s stock after selling 2,391 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Regeneron Pharmaceuticals were worth $616,498,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. SteelPeak Wealth LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 692 shares during the period. Atria Investments Inc raised its stake in Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after purchasing an additional 941 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Regeneron Pharmaceuticals by 23.2% in the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after purchasing an additional 5,495 shares during the last quarter. Tidal Investments LLC increased its holdings in shares of Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after buying an additional 711 shares during the last quarter. Finally, Sierra Summit Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $1,011,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on REGN shares. Argus lifted their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Wells Fargo & Company boosted their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Truist Financial restated a “buy” rating and issued a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $1,250.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,109.70.

Regeneron Pharmaceuticals Stock Down 1.0 %

REGN opened at $1,153.35 on Monday. The stock’s 50 day moving average price is $1,124.22 and its 200 day moving average price is $1,026.46. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The stock has a market cap of $127.08 billion, a P/E ratio of 34.07, a P/E/G ratio of 3.97 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company earned $8.79 earnings per share. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Insider Activity

In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The disclosure for this sale can be found here. Insiders sold 10,026 shares of company stock worth $11,498,705 over the last three months. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.